We will screen for participants with an echocardiogram within 60 days of the baseline visit
You may not be if
Female participants who are pregnant, lactating, or of child bearing potential
History of type 1 or type 2 diabetes mellitus by medical history or hemoglobin A1c \>7.0% at Visit 1
Clinical diagnosis of HFpEF or HFrEF by participant self-report or documented in the electronic health record
Any LVEF measure of ≤40% on past echocardiogram
Moderate or severe valve disease on echocardiogram
History of genitourinary infection
eGFR \<60 ml/min/1.73 m2 at Visit 1
Current treatment with SGLT2 inhibitor, GLP1 agonist, or DPP4 inhibitors
Participants in whom coronary revascularization by either PCI or bypass surgery is being contemplated within 6 months, or who have undergone revascularization in the prior 2 months
Significant allergy or known intolerance to SGLT2 inhibitors or any ingredient in the formulations
Participants currently experiencing any clinically significant or unstable medical condition that might limit their ability to complete the study, or to comply with the requirements of the protocol, including: dermatologic disease, hematological disease, pulmonary disease, hepatic disease, gastrointestinal disease, genitourinary disease, endocrine disease, neurological disease, and psychiatric disease
Any malignancy not considered cured (except basal cell carcinoma of the skin). A participant is considered cured if there has been no evidence of cancer recurrence for the 5 years prior to screening
Participants who have participated in studies of an investigational drug or device within 30 days prior to the screening visit
Inadequate quality echocardiographic images
Unstable coronary syndromes
Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1 or scheduled major elective surgery within 90 days after Visit 1.
Non-English speaking individuals
Clareo Health | Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
